Skip to content

Effects of sugammadex on postoperative pulmonary complications and rapid recovery after thoracoscopic pulmonary resection surgery

Effects of sugammadex on postoperative pulmonary complications and rapid recovery after thoracoscopic pulmonary resection surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300072817
Enrollment
Unknown
Registered
2023-06-26
Start date
2021-11-15
Completion date
Unknown
Last updated
2023-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative pulmonary complications

Interventions

Sugammadex group:When the train-of-four stimulation (TOF) count reached 2, the sugammadex group was given sugammadex at a dosage of 2 mg/kg
Placebo group:When the train-of-four stimulation (TOF) count reached 2, the placebo group was given equal volume of normal saline.

Sponsors

Jiangsu Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: 1)aged 18-64 years with a BMI of 18-28 kg/m², American Society of Anesthesiologists (ASA) physical status of ?-? 2)scheduled for unilateral thoracoscopic lobectomy or segmentectomy 3)patients should fully know and understand the content of the consent form, and should be willing to sign the informed consent form

Exclusion criteria

Exclusion criteria: 1) allergy to sugammadex or other drugs 2) preoperative neuromuscular diseases 3) severe hepatic dysfunction (stage 4 kidney disease or higher); severe renal dysfunction (aspartate aminotransferase or alanine aminotransferase greater than twice the upper limit of institutional normal); severe heart disease (NYHA grade ? or ?) 4)preoperative pulmonary diseases such as COPD (except GOLD1 grade: FEV1 = 80% of the predicted value), asthma, pulmonary infection, and bronchiectasis 5)previous history of lung surgery 6) postoperative transfer to intensive care unit 7)participation in other clinical studies within 30 days

Design outcomes

Primary

MeasureTime frame
The incidence of postoperative pulmonary complications;

Secondary

MeasureTime frame
Time from the end of surgery to extubation; time from drug administration to recovery of the TOF ratio (TOFr) to 0.9;the TOF ratio immediately after extubation;the length of stay in PACU;time from the end of surgery to ambulation;static and dynamic numerical rating scale (NRS) score at 24 and 48 hours after surgery;postoperative nausea and vomiting; duration of the chest tube insertion;the length of postoperative hospital stay ;hospitalization expenses;

Countries

China

Contacts

Public ContactLianbing Gu

Jiangsu Cancer Hospital

13951947684@163.com+86 139 5194 7684

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026